Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease

Cell Tissue Res. 2018 Jul;373(1):51-60. doi: 10.1007/s00441-017-2704-y. Epub 2017 Oct 24.

Abstract

Parkinson's disease (PD) is a neurodegenerative movement disorder characterized pathologically by the presence of Lewy bodies comprised of insoluble alpha (α)-synuclein. Pathological, clinical and genetic studies demonstrate that mutations in the GBA1 gene, which encodes the lysosomal enzyme glucocerebrosidase (GCase) that is deficient in Gaucher's disease, are important risk factors for the development of PD. The molecular mechanism for the association between these two diseases is not completely understood. We discuss several possible mechanisms that may lead to GBA1-related neuronal death and α-synuclein accumulation including disruptions in lipid metabolism, protein trafficking and impaired protein quality control mechanisms. Elucidating the mechanism between GCase and α-synuclein may provide insight into potential therapeutic pathways for PD and related synucleinopathies.

Keywords: Alpha (α)-synuclein; Glucosylceramide; Lysosomal dysfunction; Neurodegeneration; Protein aggregation.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Glucosylceramidase / metabolism*
  • Humans
  • Lysosomes / metabolism
  • Models, Biological
  • Mutation / genetics
  • Parkinson Disease / genetics*
  • Parkinson Disease / therapy
  • alpha-Synuclein / metabolism*

Substances

  • alpha-Synuclein
  • Glucosylceramidase